Welcome Spermosens
Today is the first trading day in Spermosens AB who are active within medical technology and specializes in the development of medical devices
The company develops products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization. The largest operations are in the Nordic market.
“Our ambition is to contribute to an improved quality of life for couples with infertility problems around the world” says John Lempert, CEO, Spermosens.
Spermosens new share issue was subscribed to approximately 652 percent of the offering, and now the company has approximately 3000 new shareholders.
“Today is the first trading day in yet another interesting growth company on Spotlight – this time active within medical technology. It is great to see the interest in the company who’s offering was oversubscribed prior to the listing. Welcome Spermosens!” says Carl-Henrik Nordberg, Head of Listing, Spotlight.
Press contact
Jenny Sondal, CMO Spotlight
+46 70 7749303, js@spotlightstockmarket.com
ABOUT SPOTLIGHT
Spotlight is the marketplace where investors and growth companies meet. At Spotlight it is easier and safer for companies to be listed. We offer an overall solution that increase the visibility for our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in approximately 160 growth companies from different businesses and countries, among those are Freetrailer, Bahnhof and Synthetic MR.
